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Untangling the immune basis of
disease susceptibility
Interactions between immune cell receptors and proteins that determine
disease susceptibility shed light on how different arms of the immune
system are involved in three viral infections and Crohn’s disease.
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hy do people respond differently to
the same infectious agent? A possi-
ble answer is that differences in the
immune responses of individuals, caused by
genetic variability between them, are responsi-
ble. Indeed, many studies have looked for asso-
ciations between genes involved in immunity
and disease outcome (Buniello et al., 2019),
and it has been found that a gene complex
called the human leukocyte antigen (HLA) sys-
tem has a central role (Matzaraki et al., 2017).
The HLA genes encode the major histocom-
patibility complex (MHC). MHC proteins are
found on the surface of cells and each one
presents peptides from proteins within the cell
(either proteins native to the cell or from foreign
entities like bacteria) to immune cells. Thus,
MHC proteins allow immune cells to recognize if
a given cell is dangerous or not. For example,
immune cells called CD8+ T lymphocytes recog-
nize cells that have been infected with viruses
because receptors on these T cells bind specific
MHC proteins loaded with viral peptides on the
surface of the infected cells. Likewise, other
types of immune cells – such as natural killer
cells, macrophages and dendritic cells – have
receptors that bind to other parts of the MHC
protein displayed by infected cells (Augusto and
Petzl-Erler, 2015; Hudson and Allen, 2016).
The HLA is extremely diverse among individu-
als. It has been assumed that the association
between some diseases and certain HLA alleles
is evidence for a central role of CD8+ T cells in
that disease. However, given that the HLA can
also interact with receptors on other immune
cells, disentangling the contributions of the dif-
ferent arms of the immune system remains a
challenge. Now, in eLife, Becca Asquith of Impe-
rial College and colleagues – including Bisrat
Debebe as first author, researchers from various
institutes in the UK and US, and the IAVI Proto-
col C Investigators – report the results of a new
approach to disentangling these contributions
(Debebe et al., 2020).
Debebe et al. reasoned that it may be possi-
ble to predict which immune cells are responsi-
ble for fighting a specific disease since receptors
from particular immune cells interact with differ-
ent regions of the MHC protein. For example,
susceptibility to a disease may be associated
with individuals carrying MHC proteins that are
similar in the region that presents protein frag-
ments to the T-cell receptor (which can be
thought of as being similar in ‘T-cell receptor
space’). If this is the case, then CD8+ T cells are
likely involved in fighting the disease. The same
reasoning can be made for associations with the
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other receptors, such as the killer immunoglobu-
lin-like receptor (KIR) receptors in natural killer
cells and leukocyte immunoglobulin-like
receptor (LILR) in myeloid cells (Figure 1).
The challenge in this method is defining MHC
similarity. Debebe et al. did so by taking an HLA
known to associate with a specific disease out-
come and predicting its ability to bind to differ-
ent immune cell receptors. Next, they compared
this predicted binding ability to that of all other
HLAs, and found the HLAs with the highest bind-
ing similarity. Finally, they checked if these HLAs
are also associated with disease susceptibility.
Debebe et al. applied this method to three
infections (human T-cell leukemia virus type one
or HTLV-1; hepatitis C virus; and HIV-1) and one
autoimmune disease (Crohn’s disease). They
used well-characterized cohorts where both the
HLA and the outcome of the disease were
known for each individual.
They studied three known HLA-outcome
associations for HTLV-1 and found that other
HLAs that were similar in T-cell receptor space
were also associated with HTLV-1. However,
other HLAs that were similar to these three
HLAs in LILR space or KIR space (see Figure 1)
were not associated with HTLV-1. Thus, they
concluded that HTLV-1 is most likely controlled
by CD8+ T cells. They also studied three HLA-
outcome associations for hepatitis C, reaching
the same conclusion: disease outcome is mostly
controlled by CD8+ T cells. For HIV-1, Debebe
et al. found that natural killer cells and CD8+ T
cells both have a role, which is consistent with
previous results (Bashirova et al., 2011;
McBrien et al., 2018). They also studied two
known HLA-outcome associations for Crohn’s
disease in a large sample (2650 individuals), but
other HLAs that were similar in T-cell, LILR or
KIR space did not have significant effect on
Crohn’s disease outcome.
The approach suggested by Debebe et al.
generates insights into which immune cells may
be involved in fighting a disease. There are two
issues that need to be explored further. First,
while we know a great deal about T-cell
Figure 1. Axes of similarity in MHC proteins. Debebe et al. showed that similarities in regions of the MHC
molecule that interact with different immune cell receptors can be thought of in terms of different ’spaces’ (which
are defined by an axis for each type of receptor). They found that MHCs that are similar in the T-cell receptor
(TCR) axis are associated with disease outcomes for HLTV-1, hepatitis C virus (HCV) and HIV-1. Disease outcomes
for HIV-1 are also associated with MHCs that show similarity in the killer immunoglobulin-like receptor (KIR) axis.
For the diseases tested, no MHCs were found to be similar in the region that interacts with the leukocyte
immunoglobulin-like receptor (LILR) carried by myeloid cells (MC). CD8: CD8+ T cells; NK: natural killer cells; blue
circle: peptide.
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receptors, we know less about KIR, and even
less about LILR binding (Hirayasu and Arase,
2015). This knowledge (or lack thereof) is part of
the definition of similarity used by Debebe et al.,
which can and should be updated as more data
becomes available (Gwozdowicz et al., 2019).
The second issue pertains to the fact that it may
be possible to define similarity in other ways,
leading to different results that provide further
insights into how genetic variability affects the
immune response.
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